HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hsiu-Ching Hsu Selected Research

Cardiovascular Diseases (Cardiovascular Disease)

1/2022Associations between fibrinogen levels and the risk of cardiovascular disease and all-cause death: a cohort study from the Chin-Shan community in Taiwan.
1/2020Statin-induced microRNAome alterations modulating inflammation pathways of peripheral blood mononuclear cells in patients with hypercholesterolemia.
12/2019Association between Plasma N-6 Polyunsaturated Fatty Acids Levels and the Risk of Cardiovascular Disease in a Community-based Cohort Study.
1/2015Total 25-hydroxyvitamin D concentration as a predictor for all-cause death and cardiovascular event risk among ethnic Chinese adults: a cohort study in a Taiwan community.
12/2014The reduced autophagic response by oxidative stress in angiotensin II-induced hypertrophic H9C2 cells causes more apoptotic cell death.
9/2013Comparison of predictive performance of various fatty acids for the risk of cardiovascular disease events and all-cause deaths in a community-based cohort.
11/2008Fasting and postchallenge hyperglycemia and risk of cardiovascular disease in Chinese: the Chin-Shan Community Cardiovascular Cohort study.
2/2008Lipoprotein(a) and cardiovascular disease in ethnic Chinese: the Chin-Shan Community Cardiovascular Cohort Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hsiu-Ching Hsu Research Topics

Disease

13Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2022 - 11/2005
8Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 02/2008
8Stroke (Strokes)
01/2022 - 01/2002
6Hypertension (High Blood Pressure)
01/2022 - 01/2002
6Atherosclerosis
08/2012 - 03/2006
4Obesity
01/2022 - 05/2006
4Coronary Disease (Coronary Heart Disease)
08/2009 - 11/2005
3Insulin Resistance
01/2022 - 11/2008
3Atherosclerotic Plaque (Atheroma)
01/2020 - 01/2007
3Type 2 Diabetes Mellitus (MODY)
05/2017 - 02/2008
2Inflammation (Inflammations)
01/2020 - 01/2012
2Hypercholesterolemia
01/2020 - 03/2010
2Coronary Artery Disease (Coronary Atherosclerosis)
06/2016 - 11/2012
2Heart Failure
12/2010 - 09/2009
2Carotid Artery Diseases
09/2009 - 08/2008
2Myocardial Infarction
03/2009 - 08/2008
2Infarction (Infarctions)
03/2009 - 08/2008
1Overweight
01/2022
1Pediatric Obesity
01/2022
1Hyperthyroidism
06/2016
1Edema (Dropsy)
06/2016
1Cardiomegaly (Heart Hypertrophy)
12/2014
1Cardiotoxicity
11/2014
1Neoplasms (Cancer)
11/2014
1Ischemic Stroke
01/2013
1Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
01/2012
1Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/2012
1Mitochondrial Diseases (Mitochondrial Disease)
01/2012
1Acute Coronary Syndrome
11/2011
1Iron Overload
06/2011
1Pathologic Constriction (Stenosis)
06/2011
1Cardiac Sudden Death (Sudden Cardiac Arrest)
12/2010
1Chronic Renal Insufficiency
09/2010
1Proteinuria
09/2010
1Hypertriglyceridemia
09/2009
1Vascular Diseases (Vascular Disease)
08/2009
1Hyperglycemia
05/2009

Drug/Important Bio-Agent (IBA)

6Biomarkers (Surrogate Marker)IBA
01/2020 - 05/2009
6Glucose (Dextrose)FDA LinkGeneric
05/2017 - 05/2006
6LipidsIBA
11/2011 - 01/2002
5ApolipoproteinsIBA
11/2012 - 01/2002
5oxidized low density lipoproteinIBA
01/2012 - 06/2007
5HDL CholesterolIBA
09/2009 - 04/2005
4C-Reactive ProteinIBA
01/2020 - 05/2006
4Fatty Acids (Saturated Fatty Acids)IBA
12/2019 - 02/2011
4LDL CholesterolIBA
08/2012 - 11/2007
3CholesterolIBA
01/2020 - 01/2007
3Eicosapentaenoic AcidIBA
11/2014 - 02/2011
3Docosahexaenoic AcidsIBA
11/2014 - 02/2011
3Proteins (Proteins, Gene)FDA Link
01/2012 - 06/2007
3Uric Acid (Urate)IBA
09/2010 - 11/2005
3Adenosine Triphosphate (ATP)IBA
02/2008 - 05/2006
3Apolipoproteins B (ApoB)IBA
11/2007 - 01/2002
2Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2020 - 03/2010
2Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
12/2019 - 09/2013
2CalciumIBA
06/2016 - 06/2011
2CreatinineIBA
03/2015 - 04/2008
2LDL Lipoproteins (beta Lipoproteins)IBA
01/2012 - 09/2009
1Fibrinogen (Factor I)FDA Link
01/2022
1TylosinIBA
01/2022
1SaltsIBA
01/2022
1Anti-Bacterial Agents (Antibiotics)IBA
01/2022
1MicroRNAs (MicroRNA)IBA
01/2020
1CarbonIBA
01/2018
1Hypoglycemic Agents (Hypoglycemics)IBA
05/2017
1DiureticsIBA
06/2016
12,4-thiazolidinedione (thiazolidinedione)IBA
06/2016
1hydroxide ionIBA
01/2015
1Myosin Heavy Chains (Myosin Heavy Chain)IBA
12/2014
1Natriuretic AgentsIBA
12/2014
1Atrial Natriuretic Factor (ANF)IBA
12/2014
1Angiotensin IIIBA
12/2014
1Mitochondrial Uncoupling ProteinsIBA
11/2014
1Doxorubicin (Adriamycin)FDA LinkGeneric
11/2014
1Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
11/2014
1Reactive Oxygen Species (Oxygen Radicals)IBA
11/2014
1FatsIBA
09/2013
1Lipoproteins (Lipoprotein)IBA
11/2012
15,5',6,6'- tetrachloro- 1,1',3,3'- tetraethylbenzimidazolocarbocyanineIBA
01/2012
1low density lipoprotein inhibitorIBA
01/2012
1N1- (2- (2,3- dihydroxyphenyl)- 5- methyl- 2- oxazoline- 4- carboxamido)- N3- (2,3- dihydroxyphenyl)- 1,3- diaminopropaneIBA
06/2011
1Omega-6 Fatty Acids (Omega 6 Fatty Acids)IBA
02/2011
1Collagen Type III (Type III Collagen)IBA
12/2010
1Hemoglobins (Hemoglobin)IBA
09/2010
1Triglycerides (Triacylglycerol)IBA
09/2009
1Apolipoprotein A-VIBA
09/2009
1AdipokinesIBA
09/2009
1ApelinIBA
09/2009
1Brain Natriuretic Peptide (Natrecor)FDA Link
09/2009
1procollagen Type III-N-terminal peptide (PIIP)IBA
09/2009
1HomocysteineIBA
08/2009
1human AOC3 proteinIBA
05/2009
1Insulin (Novolin)FDA Link
11/2008
1ElectrolytesIBA
09/2008
1PotassiumIBA
09/2008
1SodiumIBA
09/2008
1Dietary SodiumIBA
09/2008

Therapy/Procedure

2Ligation
03/2009 - 08/2008
1Therapeutics
11/2014
1Cell- and Tissue-Based Therapy (Cell Therapy)
03/2009